primary antibodies against plau (Proteintech)
Proteintech is a verified supplier 
94
Structured Review
Proteintech
primary antibodies against plau
Primary Antibodies Against Plau, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+plau/uPA%2FUrokinase+Antibody/pmc12811893-80-0-4
Average 94 stars, based on 52 article reviews
Primary Antibodies Against Plau, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+plau/uPA%2FUrokinase+Antibody/pmc12811893-80-0-4
Average 94 stars, based on 52 article reviews
primary antibodies against plau - by Bioz Stars,
2026-09
94/100 stars
Images
1) Product Images from "Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling"
Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling
Journal: Investigative Ophthalmology & Visual Science
doi: 10.1167/iovs.67.1.31
Figure Legend Snippet: In vitro experiments confirming ellagic acid (EA) target on PLAU to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.
Techniques Used: In Vitro, Western Blot, Expressing, Irradiation
Related Articles
In Vitro:Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling. Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( Western Blot:Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling. Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( Expressing:Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling. Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( Irradiation:Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling. Article Snippet: To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.To minimize nonspecific binding, the membrane was blocked with 5% non-fat milk.. Primary antibodies against PLAU ( |